Dr Reddy's Laboratories introduces Avigan in India

Dr Reddy’s Laboratories informed on Wednesday that the company has launched AVIGAN® (Favipiravir) 200 mg tablets in India.

The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co Ltd that grants Dr Reddy’s, the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. Favipiravir is an antiviral drug. It was initially developed for influenza by the pharmaceutical branch of Fujifilm, Toyama Chemical.

 AVIGAN® (Favipiravir) has been approved by Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease. Dr Reddy’s AVIGAN® comes in a complete therapy pack of 122 tablets with a two-year shelf life. To ensure accelerated access to medicine, Dr Reddy’s has initiated a free home delivery service in 42 cities in the country. It has also provided a helpline number for inquiries.

The stock closed at 4489.15, down by 0.34 per cent or Rs 15.10 per share. The intraday high is Rs 4559 and the intraday low is Rs 4479. Since the beginning of the year, the stock has given a return of 55 per cent thereby outperforming S&P BSE Healthcare Index, which gave a return of 41.5 per cent.